Detalhe da pesquisa
1.
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
BMC Cancer
; 23(1): 182, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814246
2.
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
BMC Cancer
; 22(1): 1321, 2022 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36527039
3.
Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.
Acta Oncol
; 61(12): 1499-1506, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529989
4.
Ultra-fast detection and quantification of nucleic acids by amplification-free fluorescence assay.
Analyst
; 145(17): 5836-5844, 2020 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32648858
5.
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.
Acta Oncol
; 59(12): 1547-1551, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970500
6.
Transcriptome analysis in patients with temporal lobe epilepsy.
Brain
; 142(10): e55, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504209
7.
Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients.
Neuro Oncol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695342
8.
Nivolumab reaches brain lesions in patients with recurrent glioblastoma and induces T-cell activity and upregulation of checkpoint pathways.
Cancer Immunol Res
; 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38885356
9.
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
J Immunother Cancer
; 12(5)2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38782542
10.
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.
Front Genet
; 14: 1058605, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37035751
11.
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Cancer Immunol Res
; 10(10): 1254-1262, 2022 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35969233
12.
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Oncoimmunology
; 11(1): 2023255, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35036074
13.
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
J Immunother Cancer
; 9(10)2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34607899
14.
A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data.
Cancers (Basel)
; 13(24)2021 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34944901
15.
The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
Clin Cancer Res
; 26(6): 1507-1515, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31919133
16.
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Clin Cancer Res
; 25(4): 1239-1247, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30274980
17.
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
NPJ Genom Med
; 4: 13, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31263571
18.
Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study.
Oncotarget
; 10(43): 4397-4406, 2019 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320993
19.
Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death.
Mol Cancer Ther
; 6(6): 1869-76, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17575115
20.
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.
Oncotarget
; 9(66): 32570-32579, 2018 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30220966